---
title: "Panlong Pharmaceutical: Received the acceptance notice for the application of Panlong Qining Gel Patch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253792199.md"
description: "Panlong Pharmaceutical recently received a notification from the National Medical Products Administration, confirming that its registration clinical trial application for Panlong Qining Gel Patch has been accepted. This product is based on the ancestral secret recipe of Mr. Wang Jiacheng and aims to treat knee osteoarthritis, with effects of promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain. Due to the complexity of research and clinical trials, the progress may be affected by uncertain factors"
datetime: "2025-08-20T10:35:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253792199.md)
  - [en](https://longbridge.com/en/news/253792199.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253792199.md)
generator: "portal-rs"
---

# Panlong Pharmaceutical: Received the acceptance notice for the application of Panlong Qining Gel Patch

Panlong Pharmaceutical announced that the company recently received the acceptance notice for the registration clinical trial of Panlong Seven Gel Patch issued by the National Medical Products Administration. This product is an innovative medicine based on the exclusive variety of Panlong Seven Medicinal Wine, made according to the ancestral secret formula contributed by the famous bone and injury expert Mr. Wang Jiacheng. Its main functions are to promote blood circulation and remove blood stasis, dispel wind and eliminate dampness, and reduce swelling and relieve pain, suitable for knee osteoarthritis. The early-stage research and development of the drug, as well as the long cycle and multiple stages from development, clinical trial approval to production, are easily affected by some uncertain factors, and there is still uncertainty in the clinical trial process

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [This Former Small-Cap Darling Is in Freefall, But I Like the Stock Here](https://longbridge.com/en/news/296374899.md)
- [Is it still protectionism when a national champion is part foreign-owned?](https://longbridge.com/en/news/296408762.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [03:00 ETCan Independent Critical Access Hospitals Solve the Rural Healthcare Crisis? "All Access hosted by Andy Garcia" Features Syracuse Area Health](https://longbridge.com/en/news/296188096.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**